Form 4: Revelation Biosciences Director Boosts Stake

Revelation Biosciences Director Jess Roper acquired 41,981 shares of common stock at $0.90 per share, increasing total beneficial ownership to 57,667 shares.

Summary

• Jess Roper, a Director of Revelation Biosciences, Inc. (REVB), acquired 41,981 shares of common stock.
• The transaction occurred on January 8, 2026, at a price of $0.90 per share.
• These shares are Restricted Stock Units (RSUs) granted under the 2021 Equity Incentive Plan.
• The RSUs will vest quarterly over one year from the date of grant.
• Following this acquisition, Jess Roper's direct beneficial ownership increased to 57,667 shares of common stock.

Sentiment

Score: 7

Explanation: The acquisition of shares by a director, especially through an equity incentive plan, generally indicates confidence in the company's future, which is a positive signal for investors.

Positives

• A director increasing their stake can signal confidence in the company's future prospects.
• The shares were acquired as Restricted Stock Units, aligning the director's interests with long-term shareholder value through a vesting schedule.

Future Outlook

The acquired Restricted Stock Units will vest quarterly over one year from the date of grant, indicating a future vesting schedule for these shares.

Industry Context

Insider buying, particularly by a director, can be viewed positively by the market as it suggests confidence in the company's future performance, especially in the biotechnology sector where long-term development cycles are common.

Stakeholder Impact

• Shareholders: The director's increased stake may be perceived as a positive signal, potentially boosting investor confidence.
• Management/Employees: The equity incentive plan aligns the director's interests with long-term company performance.

Next Steps

• The acquired Restricted Stock Units will vest quarterly over one year from the grant date.

Key Dates

Recommendation

While the director's acquisition of shares is a positive signal of confidence, a Form 4 filing alone does not provide sufficient fundamental or operational data to warrant a 'buy' or 'strong buy' recommendation. It suggests a 'hold' as it reinforces existing positions without introducing new significant financial performance data.

Keywords

Revelation Biosciences, REVB, Insider Trading, Form 4, Stock Acquisition, Director, Restricted Stock Units, Equity Incentive Plan